Invivyd (IVVD) Cash & Equivalents (2020 - 2026)
Invivyd's (IVVD) quarterly Cash & Equivalents came in at $226.7 million in Q4 2025, up 226.88% YoY from $69.3 million in Q4 2024, and up 166.8% on a QoQ basis from $85.0 million in Q3 2025.
Invivyd (IVVD) Cash & Equivalents (2020 - 2026) Analysis & Trends
Invivyd (IVVD) has 6 years of Cash & Equivalents data on file, last reported at $226.7 million in Q4 2025.
- Quarterly Cash & Equivalents rose 226.88% year-over-year to $226.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $226.7 million (up 226.88% YoY) and the FY2025 annual result came in at $226.7 million, up 226.88% from the prior year.
- Cash & Equivalents climbed to $226.7 million in Q4 2025, from $85.0 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $542.2 million in Q4 2021 to a low of $34.9 million in Q2 2025.
- A 5-year average of $227.9 million and a median of $181.8 million in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 371.55% — and 2022, when it plunged 83.02%.
- Tracing IVVD's Cash & Equivalents over 5 years: stood at $542.2 million in 2021, then sank by 83.02% to $92.1 million in 2022, then soared by 117.91% to $200.6 million in 2023, then slumped by 65.44% to $69.3 million in 2024, then surged by 226.88% to $226.7 million in 2025.
- The last three Cash & Equivalents figures came in at $226.7 million (Q4 2025), $85.0 million (Q3 2025), and $34.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | 160.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 160.08 Mn |
| Dec 31, 2025 | 226.69 Mn |
| Sep 30, 2025 | 84.97 Mn |
| Jun 30, 2025 | 34.91 Mn |
| Mar 31, 2025 | 48.08 Mn |
| Dec 31, 2024 | 69.35 Mn |
| Sep 30, 2024 | 106.87 Mn |
| Jun 30, 2024 | 147.88 Mn |
| Mar 31, 2024 | 189.39 Mn |
| Dec 31, 2023 | 200.64 Mn |
| Sep 30, 2023 | 181.82 Mn |
| Jun 30, 2023 | 121.95 Mn |
| Mar 31, 2023 | 126.47 Mn |
| Dec 31, 2022 | 92.08 Mn |
| Sep 30, 2022 | 278.15 Mn |
| Jun 30, 2022 | 474.89 Mn |
| Mar 31, 2022 | 532.22 Mn |
| Dec 31, 2021 | 542.22 Mn |
| Sep 30, 2021 | 478.27 Mn |
| Jun 30, 2021 | 392.51 Mn |